Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in ...

Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Research shows that digital inhalers equipped with remote monitoring capabilities may aid in predicting and identifying ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...

Digital inhalers may help predict impending acute exacerbations of chronic obstructive pulmonary disease (COPD), according to ...